论文部分内容阅读
目的评价长春瑞滨联合顺铂(NP方案)治疗转移性乳腺癌的疗效。方法34例晚期乳腺癌用长春瑞滨25mg/m2加入250ml生理盐水中快速静脉滴注第1、8天,应用长春瑞滨后予地塞米松5mg静推,再用生理盐水250ml快速静脉滴注,顺铂80mg/m2分3d第1～5天加入生理盐水500ml中静脉滴注,3周为1周期。结果CR2例,PR17例,NS9例,PD6例,总有效率(CR+PR)为58.8%,其中初治有效率为64.3%,复治有效率为50%。本组主要的毒性反应为骨髓抑制、胃肠道反应和静脉炎。骨髓抑制主要为外周血白细胞减少,发生率达75%。结论由长春瑞滨联合顺铂治疗转移性乳腺癌,可获得较好疗效,且毒性可以耐受,值得临床推广应用。
Objective To evaluate the efficacy of vinorelbine plus cisplatin (NP regimen) in the treatment of metastatic breast cancer. Methods 34 cases of advanced breast cancer with vinorelbine 25mg / m2 added 250ml saline rapid intravenous infusion of 1,8 days, after the application of vinorelbine dexamethasone 5mg static push, and then 250ml normal saline rapid intravenous infusion , Cisplatin 80mg / m2 sub-3d day 1 to 5 added saline 500ml intravenous infusion, 3 weeks for a cycle. Results CR2, PR17, NS9 and PD were 58.8%. The initial effective rate was 64.3% and the effective rate of retreatment was 50%. The main toxicity of this group of myelosuppression, gastrointestinal reactions and phlebitis. Myelosuppression is mainly peripheral leukopenia, the incidence of 75%. Conclusions The combination of vinorelbine and cisplatin in the treatment of metastatic breast cancer has good curative effect and is tolerable. It is worthy of clinical application.